ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 2565 • 2019 ACR/ARP Annual Meeting

    Pharmacokinetics and Exposure-response of Intravenous Belimumab in Children with Systemic Lupus Erythematosus

    Richard Dimelow 1, Beulah Ji2 and Herbert Struemper 3, 1GSK, Stevenage, United Kingdom, 2GSK, Uxbridge, Middlesex, United Kingdom, 3GSK, Research Triangle Park

    Background/Purpose: Belimumab is approved in adults with active SLE and for childhood-onset SLE (cSLE). PLUTO, a Phase 2, placebo-controlled, double-blind trial (114055; NCT01649765), was the first…
  • Abstract Number: 2813 • 2019 ACR/ARP Annual Meeting

    Pentameric, but Not Monomeric C-reactive Protein, Limits the SnRNP-immune Complex Triggered Type I Interferon Response: Implications for Lupus Pathogenesis

    Cecilia Svanberg 1, Helena Enocsson 1, Klara Martinsson 1, Lawrence Potempa 2, Ibraheem Rajab 2, Jonas Wetterö 1, Marie Larsson 1 and Christopher Sjöwall3, 1Linköping University, Linköping, Sweden, 2Roosevelt University, Chicago, IL, 3Department of Clinical and Experimental Medicine, Rheumatology/Division of Neuro and Inflammation Sciences, Linköping University, Linköping, Sweden

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune systemic disease affecting multiple organs and which is characterized by autoantibodies directed against nuclear constituents. Common autoantibody…
  • Abstract Number: 82 • 2019 ACR/ARP Annual Meeting

    Rab4A Increases Mitochondrial Oxidative Stress and Glutathione Disulfide Accumulation That Underlie Neurobehavioral Changes in Lupus-Prone Mice

    Thomas Winans1, Tamas Faludi 2, Brandon Wyman 1, Nick Huang 2, Joshua Lewis 1, Manuel Duarte 1, Laurence Morel 3, Frank Middleton 2 and Andras Perl 4, 1Upstate Medical University, Syracuse, 2Upstate Medical University, Syracuse, NY, 3University of Florida, Gainesville, FL, 4SUNY Upstate Medical University, Syracuse, NY

    Background/Purpose: Background/Purpose            The human GTPase HRES-1/Rab4 has been identified as a susceptibility locus for systemic lupus erythematosus (SLE) and is overexpressed in T cells of…
  • Abstract Number: 653 • 2019 ACR/ARP Annual Meeting

    Newly Diagnosed Lupus Nephritis in Elderly Predicts Good Renal Outcome: A Distinct Disease Subset from Young-onset Lupus Nephritis

    Kazuoto Hiramoto1, Hironari Hanaoka 1, Jun Kikuchi 1, Shuntaro Saito 1, Hiroshi Takei 2, Tatsuhiro Oshige 1, Noriyasu Seki 3, Hideto Tsujimoto 3, Yuko Kaneko 1 and Tsutomu Takeuchi 1, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, 3Mitsubishi Tanabe Pharma Corporation Sohyaku. Innovative Research Division, Toda-shi, Saitama, Japan

    Background/Purpose: Elderly-onset SLE is recognized to be benign disease entity with a favorable nature course. Although late-onset lupus nephritis (LN), long interval between onset of…
  • Abstract Number: 860 • 2019 ACR/ARP Annual Meeting

    Efficacy of Belimumab in Patients of Black Race with Systemic Lupus Erythematosus and High Disease Activity or Renal Manifestations

    Luiz Sergio Guedes Barbosa 1, Amit Saxena 2, Ellen M Ginzler 3, Richard Furie4, David D'Cruz 5, Susan Burriss 6, Jennifer Gilbride 7, Michelle Miller 6, James Groark 6, David Roth 6 and Beulah Ji 8, 1NUTEC - Núcleo de Terapia Especializada em Cancerologia, Cuiaba, Brazil, 2New York University School of Medicine, New York, NY, 3State University of New York Downstate Medical Center, Brooklyn, NY, 4Northwell Health, Great Neck, NY, 5The Louise Coote Lupus Unit, Guy's Hospital, London, England, United Kingdom, 6GSK, Collegeville, PA, 7GSK, Stevenage, Hertfordshire, United Kingdom, 8GSK, Uxbridge, Middlesex, United Kingdom

    Background/Purpose: Black patients have more severe SLE and more frequent lupus nephritis vs other racial groups. Efficacy and safety of intravenous (IV) belimumab was demonstrated…
  • Abstract Number: 1035 • 2019 ACR/ARP Annual Meeting

    Examining the Transcriptional Impact of Liganded ERα in the Inflammatory Milieu of Systemic Lupus Erythematosus

    Mara Lennard Richard1, Melissa Cunningham 2, Betty Tsao 3 and Gary Gilkeson 4, 1Medical University of South Carolina, Charleston, SC, 2Medical University of South Carolina, Charleston, 3Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, 4Division of Rheumatology & Immunology/Ralph H. Johnson VA Medical Center/Medical University of South Carolina, Charleston, SC

    Background/Purpose: Systemic lupus erythematosus (SLE) disproportionally affects females (9:1) over males. Despite significant research effort, the exact mechanisms behind this compelling sex bias are undefined.…
  • Abstract Number: 1395 • 2019 ACR/ARP Annual Meeting

    Risk of Immunization to Rituximab in Systemic Autoimmune Diseases and Rheumatoid Arthritis: Frequency and Risk Factors. Analysis of the Efficacy of an Alternative Treatment by Ofatumumab

    Alice Combier1, Gaetane Nocturne 2, Julien Henry 3, Rakiba Belkhir 1, Stephan Pavy 4, Clotilde Le Tiec 5, Elise Descamps 4, Raphaele Seror 6 and Xavier Mariette 7, 1Rheumatology Departement - Bicêtre Hospital, Paris, France, 2Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France., Paris, France, 3Rheumatology Departement - Bicêtre Hospital, Paris, 4Rheumatology Departement - Bicètre Hospital, Paris, France, 5Pharmacy Departement - Bicètre Hospital, Paris, France, 6Hopitaux universitaires Paris Sud, Kremlin-Bicetre, France, 7Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France

    Background/Purpose: The most widely used B cell targeted therapies in auto-immune diseases (AID) is Rituximab (RTX), a murine chimeric monoclonal antibody. Among RTX’s side effects,…
  • Abstract Number: 1592 • 2019 ACR/ARP Annual Meeting

    Defining the SLE-Associated Pulmonary Arterial Hypertension Phenotype

    Marisa Mizus1, Jessica Li 1, Daniel Goldman 2 and Michelle Petri 1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of death in SLE patients. Hypocomplementemia, antiphospholipid antibodies, and elevated antibodies to RNP and Ro are…
  • Abstract Number: 1627 • 2019 ACR/ARP Annual Meeting

    Bronchoalveolar Lavage Fluid Analysis and Mortality Risk in Systemic Lupus Erythematosus Patients with Pneumonia and Respiratory Failure

    Chien-Chih Lai1, Yi-Syuan Sun 1 and Chang-Youh Tsai 2, 1Division of Allergy, Immunology, Rheumatology, Taipei Veterans General Hospital, Taipei, Taiwan (Republic of China), 2Division of Allergy, Immunology & Rheumatology/Taipei Veterans General Hospital, Taipei, Taiwan (Republic of China)

    Background/Purpose: To evaluate the pathogens from bronchoalveolar lavage fluid (BALF) and risk factors of mortality in SLE patients with pneumonia and respiratory failure.Methods: Twenty-four SLE…
  • Abstract Number: 1936 • 2019 ACR/ARP Annual Meeting

    The Expression of the Interferon Inducible Gene SERPING1 Is Reduced by Rituximab and Correlates with Clinical Response in Systemic Lupus Erythematosus

    Liliana Santos Ribeiro1, Mariea Parvaz 2, Su-Ann Yeoh 2 and Michael Ehrenstein 2, 1University College London, London, United Kingdom, 2University College London, London, England, United Kingdom

    Background/Purpose: Abnormalities in B cells and the interferon alpha (IFN) pathway have been separately implicated in the pathogenesis of systemic lupus erythematosus (SLE). B cell…
  • Abstract Number: 2251 • 2019 ACR/ARP Annual Meeting

    Understanding Vulnerabilities in Diagnosis and Care of Childhood and Adult-Onset Lupus: A Qualitative Study

    Siobhan Case1, Corine Sinnette 2, Courtnie Phillip 2, Claire Grosgogeat 3, Karen Costenbader 2, Cianna Leatherwood 4, Candace Feldman 2 and Mary Beth Son 3, 1Brigham and Women's Hospital and Boston Children's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Boston Children's Hospital, Boston, MA, 4Kaiser Permanente, San Francisco, CA

    Background/Purpose: Systemic lupus erythematosus (SLE) poses complex diagnostic and management challenges, which may differ depending on whether SLE was diagnosed in childhood (cSLE) or in…
  • Abstract Number: 2532 • 2019 ACR/ARP Annual Meeting

    Effect of Treatment on Antiphospholipid Antibodies in SLE

    Michelle Petri1, Laurence Magder 2 and Daniel Goldman 3, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University of Maryland School of Medicine, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Unlike primary antiphospholipid syndrome patients, most SLE patients with antiphospholipid antibodies are on one or more treatments for their SLE that might affect levels…
  • Abstract Number: 2566 • 2019 ACR/ARP Annual Meeting

    Polypharmacy and Potentially Inappropriate Medication Use in Young versus Older Adults with SLE

    Dale Seguin1, Christine Peschken 2, Casandra Dolovich 1, Ruby Grymonpre 1, Phil St. John 1 and Annaliese Tisseverasinghe 1, 1University of Manitoba, Winnipeg, MB, Canada, 2University of Manitoba, Winnipeg, Canada

    Background/Purpose: Polypharmacy, typically defined as ≥ 5 medications (meds),  is a strong risk factor for adverse clinical outcomes, including delirium, falls, hospitalization, and death, especially…
  • Abstract Number: 2814 • 2019 ACR/ARP Annual Meeting

    Methionine Commits Immunometabolism and Epigenetic Regulation of BACH2 Loci in B Cells, Resulting in Biases Toward Plasmablast Differentiation in the Pathogenesis of SLE

    Mingzeng Zhang1, Shigeru Iwata 1, Maiko Hajime 1, Naoaki Ohkubo 1, Yasuyuki Todoroki 2, Hiroko Miyata 2, Jie Fan 2, Shingo Nakayamada 1, Kaoru Yamagata 1 and Yoshiya Tanaka 3, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, Kitakyushu, Japan, 2The First Department of Internal Medicine, University of Occupational & Environmental Health Kitakyushu, Japan, Kitakyushu, Japan, 3University of Occupational and Environmental Health Japan, Kitakyushu, Japan

    Background/Purpose: Amino acids play an important role in various metabolic processes. However, the role of amino acid metabolism in the regulation of human B cell…
  • Abstract Number: 83 • 2019 ACR/ARP Annual Meeting

    Dysfunction of TRIM21 Promotes Aberrant Plasmablast Differentiation in Systemic Lupus Erythematosus Due to the Reduction of TRIM21-mediated Ubiquitylation of IRF5

    Yosuke Kunishita1, Ryusuke Yoshimi 1, Reikou Kamiyama 1, Daiga Kishimoto 1, Koji Yoshida 1, Eijin Hashimoto 1, Yumiko Sugiyama 2, Takaaki Komiya 1, Natsuki Sakurai 1, Yohei Kirino 3 and Hideaki Nakajima 3, 1Department of Stem Cell and Immune Regulation / Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Department of Rheumatic Diseases / Yokohama City University Medical Center, Yokohama, Japan, 3Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    Background/Purpose: TRIM21 is a member of the tripartite motif family proteins and is one of the autoantigens which react with anti-SS-A antibody (Ab) present in…
  • « Previous Page
  • 1
  • …
  • 138
  • 139
  • 140
  • 141
  • 142
  • …
  • 150
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology